Randomized trial · people

Melanotan I: more pain-free sun time in protoporphyria trials

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this rare light-sensitivity disease, afamelanotide implants were linked to more pain-free time in the sun and better quality of life than placebo, with mostly mild side effects.

Kind
Randomized trial
Studied in
People
Published
2015
Journal
N Engl J Med

What they tested

The researchers tested whether afamelanotide implants could reduce pain and improve quality of life in people with erythropoietic protoporphyria, a severe skin condition in which sunlight triggers painful reactions.

How the study was done

Two multicenter, randomized, double-blind, placebo-controlled trials, one in the European Union (74 patients) and one in the United States (94 patients), gave either a 16 mg afamelanotide implant under the skin or a placebo (dummy) implant every 60 days. The main goal was the number of hours spent in direct sunlight without pain.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking Melanotan I? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In the US study, median pain-free time in the sun after 6 months was 69.4 hours with afamelanotide vs 40.8 hours with placebo (P=0.04). In the European Union study, median pain-free time after 9 months was 6.0 hours vs 0.8 hours (P=0.005), and the afamelanotide group had fewer phototoxic reactions, which are painful reactions to light (77 vs 146, P=0.04). Quality of life improved with afamelanotide in both trials. Side effects were mostly mild, and the serious ones were not judged to be caused by the drug.

What it doesn’t show

Both trials enrolled only patients with erythropoietic protoporphyria, so they do not test other conditions or uses. They lasted 6 to 9 months, and they were funded in part by Clinuvel Pharmaceuticals.

The paper

Langendonk et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015.

The compound

More studies on Melanotan I

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking Melanotan I? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo